Related Experiment Video
Updated: Feb 1, 2026

Boldness, Aggression, and Shoaling Assays for Zebrafish Behavioral Syndromes
Published on: August 29, 2016
FSTL1 contribute to aggressive clinical behavior in DLBCL may by activating the DIP2A/ICAM-1-mediated adhesion
Xiping Liang1, Xiaomei Zhang1, Chaoyu Wang1
1Chongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China.
Introduction:
Despite improved outcomes in diffuse large B-cell lymphoma (DLBCL) with rituximab-based therapy, cell adhesion-mediated drug resistance (CAM-DR) remains a key mechanism of treatment resistance. The role of follistatin-like protein 1 (FSTL1) in CAM-DR has not been fully elucidated.
Methods:
We conducted a retrospective analysis of newly diagnosed DLBCL patients treated with rituximab from 2019 to 2024, with special emphasis on FSTL1 expression and clinical features, and its underlying mechanism.
Results:
FSTL1 was detectable in 74.5 % of patients. Its expression was significantly elevated in DLBCL patients compared to controls (P < 0.05) and was further increased in the RR-DLBCL group (P = 0.045). FSTL1 patients exhibited more adverse clinical features, including higher incidence of extranodal involvement, more advanced stage, elevated LDH levels, and bulky masses (all p < 0.05). FSTL1 expression patients revealed a shorter overall survival (OS) (p = 0.024) and progression-free survival (PFS) (p = 0.034), with similar trend in high FSTL1 expression (P < 0.05). In vitro, increased exogenous of FSTL1 contributed to DLBCL cell proliferation, vitality, and decreased the antibody-dependent cellular cytotoxicity (ADCC) effect, whereas FSTL1 silencing reversed this trend (P < 0.05). Pathway enrichment analysis revealed an association between FSTL1 and CAM-DR. Mechanistic experiments revealed that FSTL1 may be derived from secretion by cancer-associated fibroblasts (CAFs), interacts with DIP2A on DLBCL cells and promotes ICAM-1 expression, thereby contributing to drug resistance in DLBCL.
Conclusion:
Our findings indicate that elevated FSTL1 levels may contribute to advanced clinical characteristics and worse outcomes in DLBCL. FSTL1 contributes to drug resistance likely through DIP2a/ICAM-1-mediated adhesion mechanism.
Insights
Elevated follistatin-like protein 1 (FSTL1) is linked to worse outcomes in diffuse large B-cell lymphoma (DLBCL). FSTL1 promotes drug resistance via a DIP2a/ICAM-1 adhesion mechanism, offering a potential therapeutic target.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) treatment outcomes improve with rituximab, but cell adhesion-mediated drug resistance (CAM-DR) persists.
- The specific role of follistatin-like protein 1 (FSTL1) in CAM-DR within DLBCL remains unclear.
Purpose of the Study:
- To investigate the association between FSTL1 expression and clinical characteristics in DLBCL patients.
- To elucidate the underlying mechanism of FSTL1's role in DLBCL drug resistance.
Main Methods:
- Retrospective analysis of newly diagnosed DLBCL patients treated with rituximab (2019-2024).
- Assessment of FSTL1 expression levels and correlation with clinical features and survival outcomes.
- In vitro experiments to evaluate FSTL1's effect on DLBCL cell behavior and drug resistance mechanisms.
Main Results:
- FSTL1 was detected in 74.5% of DLBCL patients, with significantly elevated levels compared to controls.
- Higher FSTL1 expression correlated with adverse clinical features (extranodal involvement, advanced stage, elevated LDH, bulky masses) and shorter overall survival (OS) and progression-free survival (PFS).
- In vitro studies showed FSTL1 promotes DLBCL cell proliferation and vitality while decreasing antibody-dependent cellular cytotoxicity (ADCC); FSTL1 silencing reversed these effects.
- FSTL1 was linked to CAM-DR, potentially secreted by cancer-associated fibroblasts (CAFs), interacting with DIP2A on DLBCL cells to promote ICAM-1 expression and drug resistance.
Conclusions:
- Elevated FSTL1 levels are associated with advanced clinical characteristics and poorer outcomes in DLBCL.
- FSTL1 contributes to DLBCL drug resistance through a DIP2a/ICAM-1-mediated adhesion mechanism.
- FSTL1 represents a potential therapeutic target for overcoming drug resistance in DLBCL.
More Related Videos
Related Concept Videos
Aggression
SN1 Reaction: Mechanism
Firstly, the haloalkane ionizes to generate a carbocation intermediate and a halide ion. This heterolytic cleavage is highly endothermic with large activation energy. The ionization of the substrate, facilitated by a...
Adhesion
Capillary action is a result of water’s adhesive tendencies. When a narrow...
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Mechanism
Binet's Contribution to Measures of Intelligence
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...

